CTRP Terminology
CTRP Agent Terminology
NCIt Antineoplastic Agent Terminology
JAK1 Inhibitor
Golidocitinib
2091134-68-6
3BY9Z3M34G
795786
795786
795786
AZD 4205
AZD-4205
AZD4205
An orally available inhibitor of Janus-associated kinase 1 (JAK1), with potential antineoplastic activity. Upon oral administration, golidocitinib inhibits JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK1-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types. Additionally, JAK1 may be a primary driver of STAT3 phosphorylation and signaling, which plays a role in neoplastic transformation, resistance to apoptosis, tumor angiogenesis, metastasis, immune evasion, and treatment resistance.
C156774
CL935810
CTRP
FDA
GDC
GOLIDOCITINIB
Golidocitinib
Golidocitinib
Golidocitinib
JAK1 Inhibitor AZD4205
JAK1 Inhibitor AZD4205
Pharmacologic Substance
GDC Terminology
GDC Therapeutic Agent Terminology
NCI Drug Dictionary Terminology
GDC Value Terminology
Pharmacologic Substance
FDA Established Names and Unique Ingredient Identifier Codes Terminology